Clinical Trial Update: Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating CPI-613 with HD cytarabine and mitoxantrone versus HD cytarabine and mitoxantrone in older patients with relapsed/refractory AML; trial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CPI-613 (devimistat)
• HD cytarabine (Cytarabine)
• Mitoxantrone (mitoxantrone)

Snippet

Sponsor: Cornerstone Pharmaceuticals | Conditions: Relapsed/Refractory Acute Myeloid Leukemia | Phase 3 | Status: TERMINATED | Results posted: 2022-12-13